Research ArticleDrug Discovery and Translational Medicine
Open Access
Identification and Characterization of Novel Receptor-Interacting Serine/Threonine‐Protein Kinase 2 Inhibitors Using Structural Similarity Analysis
Mohamed Salla, Rodrigo Aguayo-Ortiz, Gaddafi I. Danmaliki, Alaa Zare, Ahmed Said, Jack Moore, Vrajeshkumar Pandya, Robin Manaloor, Sunny Fong, Anna R. Blankstein, Spencer B. Gibson, Laura Ramos Garcia, Pascal Meier, Khushwant S. Bhullar, Basil P. Hubbard, Yahya Fiteh, Harissios Vliagoftis, Ing Swie Goping, Dion Brocks, Peter Hwang, Carlos A. Velázquez-Martínez and Shairaz Baksh
Journal of Pharmacology and Experimental Therapeutics May 2018, 365 (2) 354-367; DOI: https://doi.org/10.1124/jpet.117.247163
Mohamed Salla
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Rodrigo Aguayo-Ortiz
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Gaddafi I. Danmaliki
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Alaa Zare
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Ahmed Said
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Jack Moore
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Vrajeshkumar Pandya
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Robin Manaloor
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Sunny Fong
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Anna R. Blankstein
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Spencer B. Gibson
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Laura Ramos Garcia
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Pascal Meier
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Khushwant S. Bhullar
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Basil P. Hubbard
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Yahya Fiteh
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Harissios Vliagoftis
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Ing Swie Goping
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Dion Brocks
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Peter Hwang
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Carlos A. Velázquez-Martínez
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Shairaz Baksh
Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children’s Health Research Institute, Edmonton, Alberta, Canada (S.B.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
Identification of Novel RIPK2 Inhibitors
Mohamed Salla, Rodrigo Aguayo-Ortiz, Gaddafi I. Danmaliki, Alaa Zare, Ahmed Said, Jack Moore, Vrajeshkumar Pandya, Robin Manaloor, Sunny Fong, Anna R. Blankstein, Spencer B. Gibson, Laura Ramos Garcia, Pascal Meier, Khushwant S. Bhullar, Basil P. Hubbard, Yahya Fiteh, Harissios Vliagoftis, Ing Swie Goping, Dion Brocks, Peter Hwang, Carlos A. Velázquez-Martínez and Shairaz Baksh
Journal of Pharmacology and Experimental Therapeutics May 1, 2018, 365 (2) 354-367; DOI: https://doi.org/10.1124/jpet.117.247163
Research ArticleDrug Discovery and Translational Medicine
Identification of Novel RIPK2 Inhibitors
Mohamed Salla, Rodrigo Aguayo-Ortiz, Gaddafi I. Danmaliki, Alaa Zare, Ahmed Said, Jack Moore, Vrajeshkumar Pandya, Robin Manaloor, Sunny Fong, Anna R. Blankstein, Spencer B. Gibson, Laura Ramos Garcia, Pascal Meier, Khushwant S. Bhullar, Basil P. Hubbard, Yahya Fiteh, Harissios Vliagoftis, Ing Swie Goping, Dion Brocks, Peter Hwang, Carlos A. Velázquez-Martínez and Shairaz Baksh
Journal of Pharmacology and Experimental Therapeutics May 1, 2018, 365 (2) 354-367; DOI: https://doi.org/10.1124/jpet.117.247163
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement